0000000000414723

AUTHOR

Silvia Benemei

showing 4 related works from this author

Migraine and cluster headache – the common link

2018

Abstract Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability…

medicine.medical_specialtyNeurologyCluster headacheImplantable Neurostimulators/statistics & numerical dataPain medicineCalcitonin Gene-Related PeptideDeep Brain StimulationMigraine DisordersNitroglycerin/adverse effectsHypothalamuslcsh:MedicineTriptansReviewCalcitonin gene-related peptideBioinformatics03 medical and health sciencesNitroglycerin0302 clinical medicinemedicineHumans030212 general & internal medicineTryptamines/pharmacologyMigraineTrigeminovascular systembusiness.industryNeuromodulationCluster Headache/bloodCluster headacheAnti-CGRP (receptor) monoclonal antibodies – mAbsMigraine Disorders/bloodTrigeminovascular systemlcsh:RGeneral MedicineCalcitonin gene-related peptide (CGRP)medicine.diseaseDeep Brain Stimulation/statistics & numerical dataNeuromodulation (medicine)Tryptamines3. Good healthCalcitonin Gene-Related Peptide/antagonists & inhibitorsAnesthesiology and Pain MedicineImplantable NeurostimulatorsMigraineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugThe Journal of Headache and Pain
researchProduct

Poor patient awareness and frequent misdiagnosis of migraine: findings from a large transcontinental cohort.

2019

Background and purpose Although migraine is the second most disabling condition worldwide, there is poor awareness of it. The objective was to assess the awareness of migraine and previous diagnostic and therapeutic consultations and treatments in a large international population of migraineurs. Methods This was a multicentre study conducted in 12 headache centres in seven countries. Each centre recruited up to 100 patients referred for a first visit and diagnosed with migraine. Subjects were given a structured clinical questionnaire-based interview about the perceptions of the type of headache they suffered from, its cause, previous diagnoses, investigations and treatments. Results In all,…

AdultMalePediatricsmedicine.medical_specialtyHealth Knowledge Attitudes PracticeTension headacheMigraine DisordersPopulationcervical; error; exam; headache; management; misdiagnosis; treatment; underdiagnosisunderdiagnosismisdiagnosiCohort StudiesDiagnosis Differential03 medical and health sciencesIndirect costsYoung Adult0302 clinical medicinePhysiciansSurveys and QuestionnairesmedicineHumans030212 general & internal medicineMedical diagnosisDiagnostic ErrorsSinusitiseducationAgededucation.field_of_studytreatmentbusiness.industrycervicalHeadacheBrainexamMiddle Agedmedicine.diseaseerrorMagnetic Resonance ImagingNeurologyMigraineCohortFemaleNeurology (clinical)businessPatient awarenessTomography X-Ray Computedmanagement030217 neurology & neurosurgeryEuropean journal of neurologyReferences
researchProduct

Triptans and CGRP blockade - impact on the cranial vasculature.

2017

Abstract The trigeminovascular system plays a key role in the pathophysiology of migraine. The activation of the trigeminovascular system causes release of various neurotransmitters and neuropeptides, including serotonin and calcitonin gene-related peptide (CGRP), which modulate pain transmission and vascular tone. Thirty years after discovery of agonists for serotonin 5-HT1B and 5-HT1D receptors (triptans) and less than fifteen after the proof of concept of the gepant class of CGRP receptor antagonists, we are still a long way from understanding their precise site and mode of action in migraine. The effect on cranial vasculature is relevant, because all specific anti-migraine drugs and mig…

0301 basic medicineMigraine DisordersCalcitonin gene related peptide – CGRPNeuropeptidelcsh:MedicineMigraine modelsReviewTriptansReview ArticleCalcitonin gene-related peptide03 medical and health sciences0302 clinical medicineJournal ArticlemedicineHumansMigraine treatmentReceptorbusiness.industryTriptans Calcitonin gene related peptide – CGRP Anti-CGRP (receptor) monoclonal antibodies – mAbs Middle meningeal artery Middle cerebral arteries Migraine models Magnetic resonance angiography (MRA)Anti-CGRP (receptor) monoclonal antibodies – mAbsTrigeminovascular systemlcsh:RTriptansGeneral MedicineMiddle meningeal arterymedicine.diseaseTryptamines3. Good healthMagnetic resonance angiography (MRA)Middle cerebral arteries030104 developmental biologyAnesthesiology and Pain MedicineMigraineAnesthesiaNeurology (clinical)SerotoninbusinessNeuroscience030217 neurology & neurosurgerymedicine.drugReceptors Calcitonin Gene-Related PeptideThe journal of headache and pain
researchProduct

A PRISMA-compliant systematic review of the endpoints employed to evaluate symptomatic treatments for primary headaches

2018

Abstract Background Primary headache are prevalent and debilitating disorders. Acute pain cessation is one of the key points in their treatment. Many drugs have been studied but the design of the trials is not usually homogeneous. Efficacy of the trial is determined depending on the selected primary endpoint and usually other different outcomes are measured. We aim to critically appraise which were the employed outcomes through a systematic review. Methods We conducted a systematic review of literature focusing on studies on primary headache evaluating acute relief of pain, following the PRISMA guideline. The study population included patients participating in a controlled study about sympt…

medicine.medical_specialtyNeurologyHeadache Disorders Primaryendpointspractice guidelines as topiclcsh:MedicineTriptansPlacebopatient complianceanti-inflammatory agentsnon-steroidal03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineprimarymedicineClinical endpoint030212 general & internal medicinehumansdisabled personsclinical trialsnon-steroidal anti-inflammatorybusiness.industryAnti-Inflammatory Agents Non-Steroidallcsh:RtryptaminesCorrectionacuteGeneral MedicineGuidelineacute; clinical trials; endpoints; non-steroidal anti-inflammatory; primary headaches; prisma-guidelines; triptans; anti-inflammatory agents non-steroidal; chronic disease; disabled persons; headache disorders primary; humans; patient compliance; practice guidelines as topic; treatment outcome; tryptamines; quality of lifemedicine.diseasetriptansClinical trialAnesthesiology and Pain Medicineheadache disordersMigrainequality of lifetreatment outcomeprimary headachesNeurology (clinical)prisma-guidelinesbusinesschronic disease030217 neurology & neurosurgeryResearch Articlemedicine.drug
researchProduct